Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 5/20 | 0.61 |
| ▸ | CDK7 | P50613 | 4/20 | 0.61 |
| ▸ | CDK4 | P11802 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 9/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | CCNH | P51946 | 2/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28895475 | 0.92 | CDK7 (0.57) | CDK9CDK7CDK4MEN1KMT2A | |
| SCHEMBL31064455 | 0.89 | CDK9 (0.66) | CDK9CDK7CDK4MEN1KMT2A | |
| SCHEMBL22449329 | 0.88 | CDK9 (0.49) | CDK9CDK7CDK4CDK2GSK3B | |
| SCHEMBL31063968 | 0.85 | CDK9 (0.47) | CDK9CDK7CDK4LMNACDK2 | |
| SCHEMBL23547517 | 0.81 | CDK9 (0.45) | CDK9CDK7CDK4CDK2 | |
| SCHEMBL20971693 | 0.81 | CDK9 (0.66) | CDK9CDK7CDK4MEN1KMT2A | |
| SCHEMBL20971705 | 0.81 | CDK9 (0.66) | CDK9CDK7CDK4MEN1KMT2A | |
| SCHEMBL20971708 | 0.81 | CDK9 (0.49) | CDK9CDK7CDK4MEN1KMT2A | |
| SCHEMBL20971697 | 0.80 | CDK4 (0.71) | CDK9CDK7CDK4MEN1KMT2A | |
| SCHEMBL20971698 | 0.80 | CDK4 (0.71) | CDK9CDK7CDK4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710446-B1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | LILLY CO ELI (US) | 2022-07-20 | — | — | EP | claimed |
| CN-111344292-A | Compounds for inhibiting CDK7 | 伊莱利利公司 | 2020-06-26 | — | — | CN | claimed |
| WO-2024175024-A1 | NEW FUSED HETEROCYCLIC COMPOUND AS CDKS INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| CN-111344292-B | Compounds for inhibiting CDK7 | 伊莱利利公司 | 2022-06-03 | — | — | CN | disclosed |
| US-10787460-B2 | (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7 | ELI LILLY AND COMPANY (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3710446-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | Eli Lilly and Company (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111344292-A | Compounds for inhibiting CDK7 | 伊莱利利公司 | 2020-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787460-B2 | (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7 | CDK7, CDK9, CDK8 | CDK9 2/4885CDK7 1/4885CDK4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.